ResultsIQ

ResultsIQ › Latest results › Accretion Nutraveda Ltd

Accretion Nutraveda Ltd (ANL) quarterly results

NSE: ANL · BSE: 544694

AI summary: Results deck, Q2 FY27

Results deck of 3 Nov 2026, summarised by AI from the filing.

The company gives no numeric guidance; it only aims to expand capacity, add machinery and automation and use IPO proceeds per stated objects.

Key takeaways

  1. No numeric guidance The company gives no numeric guidance; it only aims to expand capacity, add machinery and automation and use IPO proceeds per stated objects.
  2. Margin dip EBITDA margin was 21.27% in H1 FY27 against 23.67% in H1 FY26, a decline of 241 bps, even as revenue more than doubled.
  3. Demand driver Revenue growth is attributed to increased demand for healthcare products, a diversified product portfolio and wider market reach.
  4. Raw material cost Raw materials of ₹21.68 cr in H1 FY27 were the largest cost, and the presentation gives no outlook on input costs.

Accretion Nutraveda Ltd results deck summary

Original filing on BSE

Accretion Nutraveda Ltd earnings call, investor presentation and press release summaries

Figures from the company's filings with NSE and BSE. Not investment advice.